{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:25:34Z","timestamp":1792070734182,"version":"4.4.0"},"reference-count":39,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes","award":["# PJT-175027"],"award-info":[{"award-number":["# PJT-175027"]}]},{"name":"Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award","award":["# 2019KP-NIA626990"],"award-info":[{"award-number":["# 2019KP-NIA626990"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The aldosterone to renin ratio (ARR) is the guideline-recommended screening test for primary aldosteronism. However, there are limited data in regard to the diagnostic performance of the ARR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the sensitivity and specificity of the ARR as a screening test for primary aldosteronism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the MEDLINE, Embase, and Cochrane databases until February 2020. Observational studies assessing ARR diagnostic performance as a screening test for primary aldosteronism were selected. To limit verification bias, only studies where dynamic confirmatory testing was implemented as a reference standard regardless of the ARR result were included. Study-level data were extracted and risk of bias and applicability were assessed using the QUADAS-2 tool.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten studies, involving a total of 4110 participants, were included. Potential risk of bias related to patient selection was common and present in half of the included studies. The population base, ARR positivity threshold, laboratory assay, and reference standard for confirmatory testing varied substantially between studies. The reported ARR sensitivity and specificity varied widely with sensitivity ranging from 10% to 100% and specificity ranging from 70% to 100%. Notably, 3 of the 10 studies reported an ARR sensitivity of &amp;lt;50%, suggesting a limited ability of the ARR to adequately identify patients with primary aldosteronism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ARR performance varied widely based on patient population and diagnostic criteria, especially with respect to sensitivity. Therefore, no single ARR threshold for interpretation could be recommended. Limitations in accuracy and reliability of the ARR must be recognized in order to appropriately inform clinical decision-making.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab348","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T08:19:11Z","timestamp":1621412351000},"page":"2423-2435","source":"Crossref","is-referenced-by-count":70,"title":["Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism"],"prefix":"10.1210","volume":"106","author":[{"given":"Annie","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaiya","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-3914","authenticated-orcid":false,"given":"Ankur","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology), Whakatane Hospital, Whakatane, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Davis","sequence":"additional","affiliation":[{"name":"Royal Ottawa Mental Health Centre, Ottawa, ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Endocrinology and Metabolism), Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7536-8497","authenticated-orcid":false,"given":"Alexander A","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Endocrinology and Metabolism), Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-3416","authenticated-orcid":false,"given":"Swapnil","family":"Hiremath","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-3531","authenticated-orcid":false,"given":"Gregory L","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"6","key":"2021071319532822700_CIT0001","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev."},{"issue":"14","key":"2021071319532822700_CIT0002","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"2021071319532822700_CIT0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension."},{"issue":"3","key":"2021071319532822700_CIT0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res."},{"issue":"11","key":"2021071319532822700_CIT0005","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"2021071319532822700_CIT0006","doi-asserted-by":"crossref","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"2021071319532822700_CIT0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2021071319532822700_CIT0008","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021071319532822700_CIT0009","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ecl.2019.08.002","article-title":"Primary aldosteronism diagnosis and management: a clinical approach","volume":"48","author":"Hundemer","year":"2019","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"5","key":"2021071319532822700_CIT0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension."},{"issue":"4","key":"2021071319532822700_CIT0011","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021071319532822700_CIT0012","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","article-title":"Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature","volume":"31","author":"Montori","year":"2002","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"11","key":"2021071319532822700_CIT0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.282.11.1061","article-title":"Empirical evidence of design-related bias in studies of diagnostic tests","volume":"282","author":"Lijmer","year":"1999","journal-title":"JAMA."},{"issue":"4","key":"2021071319532822700_CIT0014","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA."},{"key":"2021071319532822700_CIT0015","article-title":"Supplement to: performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: a systematic review and meta-analysis","author":"Hung","year":"2021","journal-title":"figshare"},{"key":"2021071319532822700_CIT0016","volume-title":"Covidence Systematic Review Software"},{"issue":"8","key":"2021071319532822700_CIT0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med."},{"issue":"19","key":"2021071319532822700_CIT0018","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.942","article-title":"A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations","volume":"20","author":"Rutter","year":"2001","journal-title":"Stat Med."},{"issue":"9","key":"2021071319532822700_CIT0019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol."},{"issue":"3","key":"2021071319532822700_CIT0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)."},{"issue":"6","key":"2021071319532822700_CIT0021","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension."},{"issue":"6","key":"2021071319532822700_CIT0022","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens."},{"issue":"1","key":"2021071319532822700_CIT0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/HJH.0b013e3283656b54","article-title":"Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism","volume":"32","author":"Jansen","year":"2014","journal-title":"J Hypertens."},{"issue":"9","key":"2021071319532822700_CIT0024","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1210\/js.2019-00145","article-title":"Diagnostic accuracy of the aldosterone-to-active renin ratio for detecting primary aldosteronism","volume":"3","author":"Pilz","year":"2019","journal-title":"J Endocr Soc."},{"issue":"3","key":"2021071319532822700_CIT0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1530\/eje.0.1500329","article-title":"Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication","volume":"150","author":"Seiler","year":"2004","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"2021071319532822700_CIT0026","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/HJH.0000000000001718","article-title":"Case detection in primary aldosteronism: high-diagnostic value of the aldosterone-to-renin ratio when performed under standardized conditions","volume":"36","author":"Vorselaars","year":"2018","journal-title":"J Hypertens."},{"issue":"5","key":"2021071319532822700_CIT0027","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021071319532822700_CIT0028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"issue":"8","key":"2021071319532822700_CIT0029","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021071319532822700_CIT0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension."},{"issue":"9","key":"2021071319532822700_CIT0031","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med."},{"issue":"6","key":"2021071319532822700_CIT0032","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021071319532822700_CIT0033","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension."},{"issue":"1","key":"2021071319532822700_CIT0034","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med."},{"issue":"4","key":"2021071319532822700_CIT0035","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/HYPERTENSIONAHA.111.00662","article-title":"Abnormal aldosterone physiology and cardiometabolic risk factors","volume":"61","author":"Vaidya","year":"2013","journal-title":"Hypertension."},{"issue":"10008","key":"2021071319532822700_CIT0036","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet."},{"issue":"6","key":"2021071319532822700_CIT0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021071319532822700_CIT0038","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ajh\/hpaa171","article-title":"Primary aldosteronism: strike two","volume":"34","author":"Funder","year":"2021","journal-title":"Am J Hypertens."},{"issue":"3","key":"2021071319532822700_CIT0039","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/HYPERTENSIONAHA.120.16585","article-title":"Primary aldosteronism: three strikes and out","volume":"77","author":"Funder","year":"2021","journal-title":"Hypertension."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab348\/38672236\/dgab348.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2423\/38939436\/dgab348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2423\/38939436\/dgab348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:55:20Z","timestamp":1626206120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/8\/2423\/6278133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab348","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,5,19]]}}}